10-Q: Celularity Inc. Reports Second Quarter 2024 Results Amid Financial Challenges and Strategic Shifts

Celularity Inc. reported a significant increase in revenue for the second quarter of 2024, driven by its degenerative disease segment, but faces substantial financial challenges and uncertainties about its ability to continue as a going concern.

Summary

• Celularity Inc. reported a significant increase in revenue for the second quarter of 2024, primarily driven by a 999.7% increase in product sales, largely from its Biovance 3L product.
• Despite the revenue growth, the company faces substantial financial challenges, including significant operating losses, negative cash flow, and a substantial accumulated deficit of $870.3 million as of June 30, 2024.
• The company has been actively seeking additional capital and has engaged in several financing activities, including a private placement and a loan agreement, to address its immediate working capital requirements.
• Celularity has made strategic shifts, including discontinuing certain clinical trials and focusing on its degenerative disease business, to conserve resources and improve its financial position.
• The company's management has expressed substantial doubt about its ability to continue as a going concern due to recurring losses, negative cash flows, and the need for additional capital.
• Celularity is also dealing with non-compliance issues with Nasdaq listing requirements due to delayed financial reporting, further adding to its challenges.
• The company's financial statements do not include any adjustments that may result from the outcome of these uncertainties.

Sentiment

Score: 2

Explanation: The low score is due to significant financial challenges, substantial doubt about the company's ability to continue as a going concern, non-compliance with Nasdaq listing requirements, and the need for substantial additional funding.

Positives

• Celularity reported a significant increase in revenue for the second quarter of 2024, with total net revenues of $12.1 million, up 312.2% from the same period in 2023.
• Product sales, primarily driven by Biovance 3L, increased by 999.7% to $9.96 million in Q2 2024.
• Gross profit margin improved significantly due to increased sales of Biovance 3L, which has a higher margin than other products.
• The company has successfully secured additional financing through a private placement and a loan agreement in early 2024.
• Celularity has a robust global intellectual property portfolio with over 350 patents and patent applications.

Negatives

• The company has incurred significant operating losses and negative cash flows since its inception.
• As of June 30, 2024, Celularity had an accumulated deficit of $870.3 million.
• The company has expressed substantial doubt about its ability to continue as a going concern.
• Celularity is facing non-compliance issues with Nasdaq listing requirements due to delayed financial reporting.
• The company has had to discontinue certain clinical trials due to financial constraints.
• Celularity is currently facing a number of legal proceedings.

Risks

• Celularity will need to raise additional capital to support its operations, and this additional funding may not be available on acceptable terms or at all.
• Failure to obtain necessary capital or address liquidity needs may force the company to delay, limit, or terminate operations, make further workforce reductions, discontinue commercialization efforts, or seek bankruptcy protection.
• The company is not in compliance with Nasdaq's continued listing standards and faces the risk of being delisted.
• The company is highly dependent on the success of its biomaterials products, and a decline in sales of these products would significantly harm the business.
• Celularity relies on distribution arrangements for the sale of its biomaterials products, and disruptions in these arrangements could negatively impact revenue.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• Celularity's business could be materially adversely affected by the effects of health pandemics or epidemics, as well as geopolitical conflicts, inflation, bank failures and recessions.

Future Outlook

Celularity expects to incur substantial expenses in the foreseeable future for the expansion of its degenerative disease business and ongoing internal research and development programs. The company will require substantial additional funding to build the sales, marketing, and distribution infrastructure necessary to commercialize its biomaterials products.

Industry Context

Celularity operates in the regenerative and cellular medicines industry, focusing on developing treatments for aging-related diseases, including cancer and degenerative diseases. The industry is characterized by intense competition, rapid technological advancements, and significant regulatory oversight. Companies in this space often rely on innovation and intellectual property to gain a competitive edge. The industry is also marked by high research and development costs and the need for substantial capital to fund clinical trials and commercialization efforts.

Comparison to Industry Standards

• Compared to industry standards, Celularity's focus on placental-derived allogeneic cells is innovative. Many competitors, such as Gilead Sciences and Novartis, primarily focus on autologous cell therapies, which involve using a patient's own cells.
• Celularity's revenue growth in the degenerative disease segment is notable, but its financial challenges, including significant losses and negative cash flow, are not uncommon for clinical-stage biotechnology companies. For example, bluebird bio, Inc. has faced similar financial challenges, including liquidity concerns and the need for substantial additional funding.
• Celularity's reliance on external financing and strategic partnerships is typical in the biotechnology industry. Companies like Moderna, Inc. and BioNTech SE have also utilized strategic collaborations and financing rounds to fund their research and development efforts.
• Celularity's current market capitalization and revenue are lower than those of established players like Amgen Inc. and Regeneron Pharmaceuticals, Inc., reflecting its earlier stage of development and commercialization.

Management Changes

Legal Proceedings

• The company received a Civil Investigative Demand (the Demand) under the False Claims Act, 31 U.S.C. 3729, dated August 14, 2022, from the U.S. Attorneys Office for the Eastern District of Pennsylvania.
• On April 20, 2023, Palantir commenced an arbitration with JAMS Arbitration asserting claims for declaratory relief and breach of contract relating to the Palantir MSA. The matter was settled on December 21, 2023.
• On April 17, 2023, the company filed a complaint against Evolution Biologyx, LLC, Saleem S. Saab, individually, and Encyte, LLC (collectively, Evolution) in the United States District Court for the District of New Jersey to recover unpaid invoice amounts for the sale of its biomaterial products in the amount of approximately $2.35 million, plus interest.
• On March 27, 2024, WMBE Payrolling, Inc., dba TCWGlobal, filed a complaint in the United States District Court for the Southern District of California alleging a breach of contract and account stated claims relating to a Master Services Agreement dated May 4, 2020. The matter was settled on May 7, 2024.

Related Party Transactions

• On August 21, 2023, the company entered into a $1,000 loan agreement with Dr. Robert Hariri, the company's Chairman and Chief Executive Officer, which bears interest at a rate of 15% per year, with the first year of interest being paid in kind on the last day of each month and matures on August 21, 2024. The loan maturity date was subsequently extended to December 31, 2024.
• On September 30, 2024, Dr. Hariri assumed the loans of two unaffiliated lenders who were parties to an August 21, 2023 loan agreement.
• On October 12, 2023, in order to further address the company's immediate working capital requirements, Robert Hariri, M.D., Ph.D., the company's Chairman and Chief Executive Officer, and the company signed a promissory note for $285 which bears interest at a rate of 15.0% per year.
• On March 20, 2023, the company entered into a securities purchase agreement with two accredited investors, including its Chairman and Chief Executive Officer, Dr. Robert Hariri, for an aggregate purchase price of $9,000 (of which Dr. Hariri subscribed for $2,000).
• On January 12, 2024, the company entered into a securities purchase agreement with an existing investor, Dragasac Limited, for an aggregate purchase price of approximately $6.0 million.
• On January 12, 2024, the company entered into the RWI Second Amended Bridge Loan, which provided for an additional loan in the aggregate principal amount of $15.0 million net of an original issue discount of $3.75 million.
• The company has an Amended and Restated Employment Agreement with Dr. Robert Hariri.
• The company has Consulting & Advisory Agreements with Dr. Andrew Pecora.
• The company previously had an Advisory Agreement with Robin L. Smith MD.
• The company has a business relationship with COTA, Inc. Andrew Pecora, M.D., Celularitys former President, is the Founder and Chairman of the Board of COTA and Dr. Robin L. Smith, a former member of the Companys board of directors, is an investor in COTA.
• The company has a business relationship with Cryoport Systems, Inc. The Companys Chief Executive Officer and director, Dr. Robert Hariri, M.D, Ph.D., has served on Cryoports board of directors since September 2015.
• Alexandra Hariri, the daughter of Robert J. Hariri, M.D., Ph.D., Celularity's Chairman and Chief Executive Officer, is employed by Celularity as an Executive Director, Corporate Strategy & Business Development.

Stakeholder Impact

• Shareholders: The company's financial challenges and non-compliance with Nasdaq listing requirements could negatively impact shareholder value.
• Employees: The company has implemented cost-saving measures, including a reduction in force, which has impacted employees. Further cost-cutting measures may be necessary, potentially leading to additional job losses.
• Customers: The company's focus on its degenerative disease segment and the potential discontinuation of certain clinical trials may impact the availability of certain products and services to customers.
• Suppliers: The company's financial challenges may impact its ability to pay suppliers on time, potentially straining relationships.
• Creditors: The company's significant debt and financial challenges may increase the risk of default, impacting creditors.

Next Steps

• The company needs to secure additional funding to support its operations and address its liquidity needs.
• Celularity must regain compliance with Nasdaq's continued listing standards to avoid being delisted.
• The company plans to continue exploring licensing and collaboration arrangements for its cellular therapeutics and distribution arrangements for its degenerative disease business.
• Celularity intends to focus on its degenerative disease segment and continue developing new placental biomaterial products.
• The company will need to address the material weaknesses identified in its internal control over financial reporting.

Key Dates

Keywords

regenerative medicine, cellular medicine, cell therapy, biomaterials, Biovance 3L, Interfyl, CentaFlex, placental-derived allogeneic cells, clinical trials, FDA approval, Nasdaq compliance, capital raise, going concern, intellectual property